share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Landis John B.

SEC ·  Jan 8 05:09

Summary by Moomoo AI

On January 5, 2025, John B. Landis, an insider at EyePoint Pharmaceuticals, acquired 10,000 shares of common stock through the exercise or conversion of derivative securities. The transaction was executed at a price of $0.00 per share, indicating it was likely the result of a stock option exercise or similar equity compensation plan.Following this acquisition, Landis's direct ownership in EyePoint Pharmaceuticals increased to 21,400 shares. The transaction was reported as completed, with no additional dispositions or acquisitions noted in the filing. This insider activity may be of interest to investors as it represents a significant increase in Landis's stake in the company.
On January 5, 2025, John B. Landis, an insider at EyePoint Pharmaceuticals, acquired 10,000 shares of common stock through the exercise or conversion of derivative securities. The transaction was executed at a price of $0.00 per share, indicating it was likely the result of a stock option exercise or similar equity compensation plan.Following this acquisition, Landis's direct ownership in EyePoint Pharmaceuticals increased to 21,400 shares. The transaction was reported as completed, with no additional dispositions or acquisitions noted in the filing. This insider activity may be of interest to investors as it represents a significant increase in Landis's stake in the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated